Omnipod® 5 with FreeStyle Libre sensor integration
Omnipod® 5 Automated Insulin Delivery System and FreeStyle Libre 3 Plus and Libre 2 Plus sensors: A simpler, smarter way to manage your diabetes
Experience the convenience of the only tubeless automated insulin delivery system integrated with the FreeStyle Libre 3 Plus and FreeStyle Libre 2 Plus sensors. With up to 15 days of continuous sensor wear, you can monitor your glucose levels and manage your Pod all from one place, your dedicated Omnipod 5 controller. This seamless integration is designed to offer another choice to manage diabetes your way.
How the Omnipod 5 System works
When paired with a compatible sensor like the FreeStyle Libre 3 Plus or FreeStyle Libre 2 Plus sensor, Omnipod 5 automatically delivers insulin for up to three days (72 hours), adjusting insulin levels every five minutes to help protect against highs and lows1,2 — day and night, even while you sleep. Clinical and real world evidence shows Omnipod® 5 can support more than 80% time in range with optimised settings3.
Key features - Omnipod 5 with FreeStyle Libre 3 Plus and FreeStyle Libre 2 Plus sensor integration
- Check glucose and manage insulin delivery directly from the dedicated Omnipod 5 controller
- Convenient 15-day sensor wear
- Works with Omnipod 5 Pods compatible with FreeStyle Libre 3 Plus or FreeStyle Libre 2 Plus sensor
- Caregiver connection via the LibreLinkUp app.
See Omnipod® 5 in action
Having that extra level of security and the algorithm just doing its thing in the background is honestly just lifechanging.
Timothie Jenkinson
Podder® since 2022
Omnipod 5 reduces the burden of diabetes, it increases your quality of life and I couldn’t have even imagined something like this when I was first diagnosed.
Lydia P.
Podder® since 2014
You can almost forget about having type one wearing this pump...it's given me the first idea of what it's like to live with a working pancreas.
Pete Davies
Podder® since 2024
Start your journey with tubeless, automated insulin delivery
Explore Omnipod® 5 your way: try it, see it in action, or speak with someone to learn more.
Have questions about Omnipod® 5 and FreeStyle Libre integration?
Check out our complete list of FAQs and step-by-step integration guide to learn more about Omnipod® 5 with FreeStyle Libre integration and get answers to common questions.
1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (3.9-10.0 mmol/L or 70- 180mg/dL) in adults/adolescents as measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, P<0.0001. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in children as measured by CGM: ST = 52.5%, 3-mo Omnipod 5 = 68.0%, P<0.0001. Mean time in hyperglycaemic range (>10.0 mmol/L or >180mg/dL) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 28.9% vs. 22.8%; 44.8% vs 29.7%, P<0.0001, respectively. Mean time in hypoglycaemic range in adults/adolescents (<3.9 mmol/L or <70mg/dL as measured by CGM) as measured by CGM: ST = 1.89%, 3- mo Omnipod 5 = 1.32%, P<0.0001. Mean time in hypoglycaemic range in children (<3.9 mmol/L or <70mg/dL as measured by CGM): ST = 2.21%, 3-mo Omnipod 5 = 1.78%, P<0.0456.
2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-daystandard therapy (ST) phase followed by a 3- month AID phase with Omnipod 5 system. Mean time in range (3.9-10.0 mmol/L or 70- 180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 57.2% vs 68.1%, P<0.0001. Mean time in hyperglycaemic range (>10.0 mmol/L or >180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 39.4% vs. 29.5%, P<0.0001, respectively. Mean time in hypoglycaemic range (<3.9mmol/L or <70mg/dL as measured by CGM) ST = 3.43% vs Omnipod 5: 2.46%, P<0.0001.
3. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014.
Note: This system is not compatible with LibreLinkUp and LibreView Apps. Your healthcare provider can view glucose and Omnipod 5 data using Glooko
During the first 12 hours of use of a FreeStyle Libre 2 Plus Sensor, use a fingerstick reading from a BG meter before making treatment decisions. After the first 12 hours, you can tap “Use Sensor” to use the value and trend in the SmartBolus Calculator. If your glucose alarms and readings from the System do not match symptoms or expectations, use a fingerstick blood glucose value from a blood glucose meter to make diabetes treatment decisions [or a user-initiated bolus].
Intended Purpose as per Instructions for Use for The Omnipod 5 Automated Insulin Delivery System:
The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin. The Omnipod 5 System is intended to operate as an automated insulin delivery system when used with compatible Continuous Glucose Monitors (CGM). When in Automated Mode, the Omnipod 5 System is designed to assist people with type 1 diabetes in achieving glycaemic targets set by their healthcare providers. It is intended to modulate (increase, decrease or suspend) insulin delivery to operate within predefined threshold values using current and predicted sensor glucose values to maintain blood glucose at variable target glucose levels, thereby reducing glucose variability. This reduction in variability is intended to lead to a reduction in the frequency, severity, and duration of both hyperglycaemia and hypoglycaemia. The Omnipod 5 System can also operate in a Manual Mode that delivers insulin at set or manually adjusted rates. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with U-100 rapid acting insulin.
Warning: DO NOT start to use the Omnipod® 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over delivery or under-delivery of insulin, which could lead to hypoglycaemia or hyperglycaemia.
Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide on Omnipod.com/safety for complete safety information including indications contraindications, warnings, cautions, and instructions.